Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00315_DB01200_nanopub.RAi17buyrVo83VYWxXdw8JqY-HqCX1Iu9UzF9kCgyJI-U#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00315_DB01200 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00315_DB01200 label "DDI between Zolmitriptan and Bromocriptine - Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, bromocriptine, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated. Use of two serotonin modulators, such as zolmitriptan and bromocriptine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. [drugbank_resource:DB00315_DB01200]" assertion.
- drugbank_resource:DB00315_DB01200 identifier "drugbank_resource:DB00315_DB01200" assertion.
- drugbank_resource:DB00315_DB01200 title "DDI between Zolmitriptan and Bromocriptine - Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, bromocriptine, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated. Use of two serotonin modulators, such as zolmitriptan and bromocriptine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy." assertion.
- drugbank:DB00315 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00315_DB01200 assertion.
- drugbank:DB01200 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00315_DB01200 assertion.